A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacodynamics
- Sponsors Regeneron Pharmaceuticals
- 01 Aug 2021 Primary endpoint (Change in Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive domain Spatial Working Memory (SWM) strategy score) has not been met according to the results published in the Atherosclerosis
- 01 Aug 2021 Results published in the Atherosclerosis
- 04 May 2020 Status changed from active, no longer recruiting to completed.